Genzyme's FDA issues remain unresolved

Genzyme suffered a surprising regulatory setback in plans to expand production of its treatment for Pompe disease, after the company had issued an optimistic outlook based in part on its prediction that the expansion would be cleared. Report

Suggested Articles

AstraZeneca
Pharma

NICE shuts out AZ's Tagrisso—and dings J&J's Stelara, too

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

by Carly Helfand
jnj
Pharma

J&J's expects last year's copycat pain to 'bleed into 2020'

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

by Eric Sagonowsky
Lonza headquarters
Manufacturing

Lonza's next CEO to be pharma or biotech vet, chairman says

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.

by Eric Palmer